Arena is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs.
Our internally discovered and developed drug, BELVIQ® (lorcaserin HCl), is approved by the US Food and Drug Administration and now available in the United States. Following are links to certain additional information:
We have granted exclusive marketing and distribution rights for BELVIQ to Eisai Inc. and Eisai Co., Ltd., for most territories worldwide; to Ildong Pharmaceutical Co., Ltd., for South Korea; to CY Biotech Company Limited for Taiwan; and to Teva Pharmaceutical Industries Ltd.’s local Israeli subsidiary, Abic Marketing Limited, for Israel.
We are exploring BELVIQ’s therapeutic potential in combination with other drugs and for other indications.
We are utilizing our validated discovery and development approach to selectively advance our pipeline of internally discovered, oral drug candidates.